Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

He is currently working on his eighth, ninth and tenth books. A stockholder has filed a derivative lawsuit against the board of directors of Hims & Hers, the fast‑growing telehealth platform best ...

HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...